Nosopharm SAS
110 allée Charles Babbage
Espace Innovation 2, Parc Scientifique G. Besse
Nîmes
30000
France
Tel: 33-0-466-265-321
Fax: 33-0-486-556-342
Website: http://www.nosopharm.com
About Nosopharm SAS
Nosopharm is a biotechnology company specialized in the research and development of new antibacterial molecules. Nosopharm discovered and developed NOSO-95179, a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. Nosopharm has developed a unique expertise in the discovery of natural bioactive products stemming from the Xenorhadbus and Photorhabdus microbial genus and in the medicinal chemistry of Odilorhabdin, the new class of antibiotics to which NOSO-95179 belongs. Founded in 2009, Nosopharm is based in Lyon, France, and has a staff of seven.YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CEO: Philippe Villain-Guillot
CSO: Maxime Gualtieri
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW NOSO PHARMA:
Tweets by Nosopharm
7 articles about Nosopharm SAS
-
Nosopharm welcomes Jacques Biton and Frédéric Hammel to its supervisory board
11/5/2019
Nosopharm, a company dedicated to the research and development of new anti-infective drugs, announces changes to its supervisory board: Jacques Biton has been appointed as chairman, taking over from Gilles Alberici, while Frédéric Hammel joins the board as a member, representing Elaia Partners.
-
Nosopharm and Evotec enter into collaboration to accelerate development of novel antibiotics
7/3/2019
Nosopharm and Evotec SE announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.
-
Nosopharm appoints Dr Sarah Gould as chief development officer
11/12/2018
Dr Gould brings her substantial expertise and network to the anti-infective company at a crucial time, ahead of entering the clinical stage with lead candidate NOSO-502
-
LYONBIOPOLE Will Unite Leading French Biotech Actors at the 2018 BIO International Convention
5/31/2018
Lyonbiopole the French "bio-cluster" based in the Auvergne-Rhône-Alpes region, will unite 35 innovative organizations at the 2018 edition of the BIO International Convention.
-
Nosopharm Receives €1 Million Loan From Bpifrance
2/12/2018
This loan will enable Nosopharm to undertake CMC development and regulatory preclinical research for its main drug candidate, NOSO-502.
-
Nosopharm Bolsters Supervisory Board
12/6/2017
Alberici will be Nosopharm's new chairman.
-
Nosopharm SAS Raises €2.4 Million ($2.6M) To Develop A Novel Antibiotic Class
3/29/2017